Platinum-based neoadjuvant chemotherapy in BRCA1-positive breast cancer: a retrospective cohort analysis and literature review

• Published in: Hereditary cancer in clinical practice Vol. 16; no. 1; p. 9
• Main Authors: Sæther, Nikolai Havn, Skuja, Elina, Irmejs, Arvids, Maksimenko, Jelena, Miklasevics, Edvins, Purkalne, Gunta, Gardovskis, Janis
• Format: Journal Article
• Language: English
• Published: Poland BioMed Central Ltd 27.04.2018; BioMed Central; BMC
• Subjects: BRCA mutations; BRCA1; Breast cancer; Cancer; Care and treatment; Chemotherapy; Cisplatin; Genetic aspects; Neoadjuvant; Patient outcomes; pCR; Platinum; Neoadjuvant; Breast cancer; BRCA1; Platinum; Cisplatin; pCR
• ISSN: 1731-2302; 1897-4287; 1897-4287
• DOI: 10.1186/s13053-018-0092-2

There is increasing evidence of high platinum sensitivity in -associated breast cancer. However, evidence from randomized trials is lacking. The aim of this study was to analyze the results of platinum-based chemotherapy for BRCA1-positive breast cancer in a neoadjuvant setting. A retrospective study was performed by obtaining information from patient files. The results were compared with the available data from a literature review. Twelve female patients with gene mutations who had stage I to III breast cancers were eligible for evaluation. They received platinum-based neoadjuvant chemotherapy between 2011 and 2016. Eleven patients received a combination of cisplatin and doxorubicin, and one patient received carboplatin and docetaxel. All patients underwent mastectomy after chemotherapy. Ten patients (83%) achieved pathological complete remission (pCR). The observed pCR rate was comparable to existing results found in similar studies. The results of the study confirm the high pCR rate in BRCA1-positive breast cancer after platinum-based neoadjuvant chemotherapy. Larger randomized studies and longer follow-up times are necessary to evaluate the role of platinum-based therapies in BRCA1-positive breast cancer.